Galapagos set for small molecule and biologics pivot after cell therapy exit
But the Belgium biotech’s decision to winddown the cell business will cause it to cut around 90 percent of its headcount.
List view / Grid view
But the Belgium biotech’s decision to winddown the cell business will cause it to cut around 90 percent of its headcount.
New research has shown that complex collaborations and partnerships are increasing, while licensing agreements are decreasing in the rare disease space.
18 June 2015 | By Victoria White
Galapagos has completed recruitment for the Phase 2 Proof-of-Concept study in ulcerative colitis with GPR84 inhibitor GLPG1205...